Introduction
Muscle harbors its own progenitor cells and has the potential to regenerate from an array of injuries including traumatic, inflammatory, degenerative, and wasting disorders. Clinicians who treat these disorders, however, are faced with the reality that lost muscle bulk and strength are frequently never completely regained. There are currently no approved medications specifically designed to improve and hasten muscle regeneration. One recent approach to this clinical problem has been to attempt to modulate myostatin, an endogenous, negative regulator of muscle growth. This article will briefly review the background science of this muscle-specific growth factor and discuss recent findings suggesting its potential as a therapeutic target for a wide range of muscle disorders.
A muscle-specific, transforming growth factor beta family member Myostatin, originally named growth differentiation factor 8, was identified through its homology to other members of the transforming growth factor-b (TGF-b) superfamily [1] . It is expressed almost exclusively in developing and mature skeletal muscle. Genetically engineered mice lacking myostatin have a dramatic hypermuscular phenotype. Homozygous myostatin null mice are approximately 30% larger than their littermates, due entirely to diffusely increased muscle mass. Both axial and appendicular muscles are enlarged, weighing two to three times those of their wild-type counterparts. On histologic analysis, the mutant muscle appears normal with the exception of exhibiting both muscle fiber hypertrophy (increased fiber size) and hyperplasia (increased fiber number) [1] . Other animal models with altered myostatin function confirm the importance of myostatin in postnatal muscle growth and reveal that the degree of muscle fiber hypertrophy and/or hyperplasia is in part secondary to the timing and mode of myostatin inhibition during development and postnatal life [2 • ]. These characteristics of myostatindeficient animals indicate that myostatin normally functions as a negative regulator of muscle growth.
Myostatin shares several structural features with other members of the TGF-b superfamily. It is synthesized as a prepro-protein by muscle. Myostatin is secreted and proteolytically processed yielding a propeptide and active C-terminal domain [3] . A disulfide-linked dimer of myostatin C-terminal domains circulates in the blood as a latent complex, inhibited by a noncovalent bond to its own propeptide [3, 4] . In vitro, myostatin can be activated by dissociation of the propeptide after proteolytic cleavage by a metalloproteinase of the bone morphogenetic protein (BMP)/tolloid family, and this is postulated to be an in vivo mechanism for activation [5] . The circulating inhibitory complex also contains FLRG (follistatin-related gene) and GASP-1 (growth differentiation factor associated protein-1 [6, 7] . GASP-1 binds to the pro-region and has domains found in protease inhibitors, suggesting that it may act to inhibit the BMP/tolloid metalloproteinases that cleave the propeptide [7] . 
Inhibition of muscle progenitor cells
The development of skeletal muscle in vertebrates arises from embryonic and fetal myoblasts that by birth have differentiated into multinucleated, postmitotic myofibers. Postnatal muscle growth and regeneration are largely dependent on satellite cells that reside in a quiescent state between the sarcolemma and muscle fiber basal lamina. A variety of stimuli, such as injury to the myofiber, activate the satellite cells to proliferate and differentiate into mature myofibers. The potential of satellite cells to repopulate and regenerate muscle is quite remarkable, as seen in experimental myotoxin injuries where after only 3 to 4 days after complete destruction of myofibers, myogenic progenitor cells have rapidly repaired the damaged muscle with nascent myofibers.
Several lines of evidence indicate that myostatin acts to keep muscle progenitor cells in a quiescent state. Myostatincoated beads down-regulate expression of myogenic regulatory factors and lead to deficient limb muscle formation in developing chick embryos [13] . Recombinant myostatin inhibits the proliferation and differentiation of stable C2C12 myoblasts, primary bovine myoblasts, and mouse satellite cells in culture [14] [15] [16] [17] [18] 19 • ]. Conversely, myoblasts and satellite cells cultured from myostatin null animals proliferate and differentiate more rapidly [18,19 • ] . A major function of myostatin therefore appears to be to maintain myoblasts and satellite cells in a quiescent state, and when myostatin levels are reduced, such as from injury to the myofiber, these muscle progenitor cells are released from growth arrest.
An intriguing question that has not been fully investigated is whether myostatin also plays a role in determining cell lineage. Animals lacking myostatin have been found to develop less connective tissue [20] and adipose tissue [1, 21, 22 • ] as well as increased muscle. In dystrophic animals, fibrosis and fatty replacement are decreased in the absence of myostatin [23] . These findings raise the question of whether a pluripotent progenitor cell having the ability to pursue alternate pathways of myogenesis, adipogenesis, or fibrogenesis is directed away from myogenesis in the presence of myostatin. Potentially in support of such a hypothesis, high concentrations of myostatin recombinant protein applied to multipotent mesenchymal cells C3H 10T(1/2) was recently reported to inhibit myogenesis with decreased expression of myogenic regulatory factors and stimulate adipogenesis with up-regulation of adipogenic markers C/EBPa and adiponectin [24 • ]. Others have seen only a very small induction of adipogenesis with myostatin compared with other TGF-b family members, such as BMP2 and BMP7, and this question of cell fate will require additional investigation [9] .
Muscle regeneration in the absence of myostatin
If a major function of myostatin is inhibition of satellite cells, then in the absence of myostatin, one would anticipate enhanced muscle regenerate. This appears to be true from studies of acute and chronic muscle injury in mice. Muscle from myostatin null animals acutely injured with cardiotoxin express myogenic regulatory factors and regenerate large-diameter myofibers earlier than injured controls with normal myostatin [19 • ].
Chronic muscle injury is exhibited in the mdx mouse model of muscular dystrophy, where repeated cycles of muscle degeneration and regeneration result from the loss of dystrophin. Limb muscles are only moderately affected, exhibiting excellent regeneration. However, the diaphragm more closely parallels human disease with fibrosis and fatty replacement of muscle over time. Mdx mice genetically lacking myostatin are more muscular with greater functional strength than their mdx counterparts. Diaphragms of 9-month-old and 18-month-old animals show significantly decreased fibrosis in the absence of myostatin, with a virtual absence of fatty replacement [19 • ,23] . Mdx mice expressing the dominant negative ActRIIB similarly showed increased muscle mass and decreased interfascicle space [25] . Blockade of myostatin using intraperitoneal injections of myostatin-neutralizing antibodies resulted in increased muscle mass, absolute force, and functional strength, indicating that postnatal inhibition of myostatin alone has measurable effects on muscle growth and regeneration in the mdx model [26] .
Myostatin in humans
Myostatin is highly conserved across species with 100% amino acid identity in its active C-terminal domain among mouse, rat, pig, chicken, and human. The function of myostatin as a negative regulator of muscle growth is similarly conserved. 'Double-muscled' cattle known for their massive muscle bulk and low fat content have been found to be natural myostatin mutants [27] [28] [29] . We have recently described a loss-of-function mutation in the human gene for myostatin associated with gross muscle hypertrophy in a child, suggesting that myostatin also plays an important role in regulating muscle mass in humans [22 • ].
A German baby came to medical attention because of extensively developed musculature [22 • ]. Ultrasonography showed that the cross-sectional plane of the patient's quadriceps muscle was 7.2 SD above the mean value for 10 age-matched and sex-matched controls (6.7 cm 2 vs 3.13 ± 0.49 cm 2 ). The subcutaneous fat pad was 2.88 SD below the mean value for controls, and there was no difference in the diameter of the femoral bone between the patient and controls. A single base pair substitution at the splice donor site of the first intron was detected in both alleles of the patient and one allele of his mother but not in 200 controls. Expression of genomic wild-type and mutant constructs in vitro showed that approximately 70% of the mutant construct was misspliced with a 108-bp insertion from intron 1 that would predict a premature termination codon. No myostatin protein could be detected from this transcript in vitro or from the child's serum. The discovery of this human mutation has provided strong evidence that myostatin plays an important role in regulating muscle mass in humans.
The human gene for myostatin resides on chromosome 2q [29, 30] . The gene is composed of three exons and two introns and is normally processed to produce a 3.1-kb mRNA expressed in human skeletal muscle [30] . Additional mutations in the human myostatin gene have been sought in association with response to strength training and with strength in the elderly [31, 32] . Six missense substitutions in conserved amino acid residues have been identified (A55T, R65H, K153R, E164K, P198A, and I225T) [31, 32] . In addition, two polymorphisms within the 5#UTR have been identified [32] . The K153R variant appears to be a common polymorphism, and there are suggestions of association with muscle strength [31, 32] .
Studies aiming to determine myostatin levels in humans have been hampered in part by very low circulating levels of myostatin in humans, compared with rodents, and difficulties in producing specific antibodies to the myostatin protein, which is not only highly conserved but also highly homologous to another TGF-b family member, growth differentiation factor 11.
Therapeutic approaches
Because the function of myostatin is conserved in humans, there are great expectations that the enhancement of muscle regeneration from myostatin inhibition observed in animal models will apply to human disease. Numerous strategies can be used to develop therapeutic agents to decrease myostatin signaling, including decreasing the biosynthesis of myostatin, blocking myostatin extracellular activity, or inhibiting the intracellular signal transduction. The first therapeutic agents developed to inhibit myostatin signaling have been neutralizing antibodies. In preclinical studies, monoclonal antibodies were developed by immunizing myostatin null mice to recombinant myostatin, and these antibodies were screened by their ability to bind to and inhibit the signaling of myostatin [33] . Wyeth has subsequently developed a humanized, anti-myostatin antibody called MYO-029 and is sponsoring a multicenter phase I/II trial of this myostatin inhibitor in adult patients with muscular dystrophy (www.clinicaltrials. gov). If safe and effective at increasing strength in the setting of muscular dystrophy, MYO-029 or similar agent will hopefully be tested for its ability to stimulate muscle regeneration in a number of other clinical settings including inflammatory myopathies, cachexia, and sarcopenia.
In addition to neutralizing antibodies, there are a number of endogenous inhibitors of myostatin, including the myostatin propeptide, follistatin, FLRG, and GASP-1, which could potentially be modified for use as therapeutic agents. As described above, the myostatin propeptide forms a noncovalent bond with the active C-terminal domain, inhibiting signal transduction until the propeptide is proteolytically processed. Wild-type myostatin propeptide is unstable in vivo, but a propeptide modified so that it is not susceptible to the BMP/tolloid family of metalloproteinases has a dramatic effect on muscle mass when injected intraperitoneally [5] . Mice injected for 4 weeks with 10 mg/kg of the modified propeptide fused to immunoglobulin G (IgG)-Fc had an 18-27% increase in weight of each skeletal muscle examined versus 10-16% muscle weight increase for the JA-16 anti-myostatin antibody and no increase for wild-type propeptide fused to IgG-Fc [5] . When wild-type propeptide fused to IgG-Fc was injected at the same dose into mdx mice, however, significant increases in muscle weights as well as improved pathophysiology were reported [34] . The reason for these apparent contradictory results is not clear; however, the mdx study did involve treatment over a longer time period (3 months) and of dystrophic rather than normal muscle. A modified myostatin propeptide or protease inhibitor that specifically blocks the function of the putative metalloproteinase responsible for cleaving the endogenous myostatin propeptide are potential future therapeutic agents.
Follistatin is a secreted glycoprotein that inhibits the activity of a number of TGF-b family members. There is significant data that follistatin is an in vivo inhibitor of myostatin [3,35 •• ]. Follistatin binds myostatin with high affinity, is co-expressed with myostatin in somites, and prevents myostatin-mediated inhibition of limb muscle development in chick embryos [35 •• ] . However, the inhibitory effects of follistatin are clearly not specific to myostatin even in regard to muscle growth. Transgenic mice overexpressing follistatin in skeletal muscle have increased muscle weights of up to 327%, markedly in excess of those in the myostatin null mice, suggesting that follistatin is inhibiting other TGF-b family members in addition to myostatin during muscle growth [3] . If the lack of specificity of follistatin can be circumvented, follistatin may be a powerful target for therapeutic agents. In fact, deacetylase inhibitors, which include the popular drug valproate, up-regulate the expression of follistatin in myotubes and induce myoblast fusion into myotubes [36 •• ] . Alternatively, FLRG and GASP-1, which bind to and inhibit circulating myostatin, may prove to be more specific inhibitors of myostatin for therapeutic use [6, 7] .
Conclusion
Since 1997, when the cloning and characterization of myostatin as a novel TGF-b family member was first published, rapid advances have been made to the point where an inhibitor of myostatin entered clinical trials in early 2005. This is in part due to the appeal of this musclespecific growth factor that when inhibited produces such dramatic images of increased muscularity and in part due to good collaborative efforts between academia and industry. As reviewed in this article, inhibition of myostatin is a promising therapy for muscle regeneration for a number of reasons including myostatin's specificity for skeletal muscle, its extreme conservation across species and its direct effect on muscle progenitor cells. Although inhibition of myostatin with neutralizing antibodies is the first to enter clinical trials, it may not be the most specific or potent and there will doubtlessly be additional inhibitors to study in the future. Also, myostatin inhibitors may be the first therapies specifically designed for muscle regeneration, but they will not be the cure for most muscle diseases. Myostatin inhibition does not address the underlying pathophysiology of inflammatory myopathies, muscular dystrophies, or cachexia. Effective treatment of these disorders in the future will likely be combination therapies, underlying the importance of private and government funding of multiple strategies to combat muscle disease.
